EKF Diagnostics Holdings ( (GB:EKF) ) just unveiled an update.
EKF Diagnostics Holdings plc announced it will release its full-year results for 2024 on March 25, 2025. The company will host two investor presentations on the same day, one online and one in-person in London, to discuss the results. These events are open to existing and potential shareholders, providing an opportunity for stakeholders to engage directly with the company’s executive chair and CFO. This approach reflects EKF’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is an AIM-listed global diagnostics business specializing in point-of-care analyzers, particularly in hematology and diabetes, as well as life sciences services that include the manufacture of enzymes and custom products for diagnostic, food, and industrial applications. The company is headquartered in Penarth, near Cardiff, and operates five manufacturing sites across the US and Germany, distributing products to over 120 countries worldwide.
YTD Price Performance: -20.56%
Average Trading Volume: 379,302
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £98.46M
See more insights into EKF stock on TipRanks’ Stock Analysis page.